Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Qinglin Fei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4170-2215; OpenAlex author ID A5055915202, A5060087570. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. First author DOI 10.1007/s00535-026-02468-4↗
  2. Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma. First author DOI 10.1016/j.ygeno.2025.111048↗
  3. Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. Co-author DOI 10.1186/s13046-025-03563-9↗
  4. Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway. Co-author DOI 10.3724/abbs.2023286↗
  5. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1002/ijc.34468↗
  6. Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2023.216411↗
  7. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. Co-author DOI 10.1038/s41419-023-06313-x↗
  8. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.16879↗
  9. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  10. TGF-β1-induced RAP2 regulates invasion in pancreatic cancer. Co-author DOI 10.3724/abbs.2022015↗
  11. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03463-9↗
  12. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Co-author DOI 10.1038/s41419-020-02787-1↗
  13. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma Co-author DOI 10.1097/jp9.0000000000000055↗
  14. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. First author DOI 10.1080/2162402x.2019.1581529↗
  15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0822-6↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaizhou Jin · 10 shared papers, 2022–2026 · strength 1.95
  2. Long‐Yun Ye · 9 shared papers, 2022–2026 · strength 1.78
  3. Weiding Wu · 9 shared papers, 2022–2026 · strength 1.72
  4. Xianjun Yu · 8 shared papers, 2022–2026 · strength 1.48
  5. Saimeng Shi · 7 shared papers, 2022–2025 · strength 1.26
  6. Duancheng Guo · 3 shared papers, 2023–2025 · strength 0.63
  7. Zhenyu Liao · 4 shared papers, 2022–2023 · strength 0.62
  8. Tianjiao Li · 4 shared papers, 2022–2023 · strength 0.62
  9. Xianchao Lin · 5 shared papers, 2019–2021 · strength 0.53
  10. Yu Pan · 5 shared papers, 2019–2021 · strength 0.53
  11. Heguang Huang · 5 shared papers, 2019–2021 · strength 0.53
  12. Huiru Zhang · 3 shared papers, 2022–2023 · strength 0.46
  13. Fengchun Lu · 4 shared papers, 2019–2021 · strength 0.41
  14. Zelin Hou · 3 shared papers, 2019–2021 · strength 0.31
  15. Xuan Lin · 2 shared papers, 2022–2023 · strength 0.30
  16. Zhiwen Xiao · 2 shared papers, 2022 · strength 0.29
  17. Xianjun Yu · 1 shared paper, 2025 · strength 0.24
  18. Jianhui Yang · 1 shared paper, 2025 · strength 0.23
  19. Weiding Wu · 1 shared paper, 2025 · strength 0.23
  20. Minggui Pan · 2 shared papers, 2019 · strength 0.18
  21. He Cheng · 1 shared paper, 2022 · strength 0.16
  22. Chen Liu · 1 shared paper, 2022 · strength 0.16
  23. Wei Chen · 1 shared paper, 2023 · strength 0.16
  24. Tianhong Teng · 1 shared paper, 2020 · strength 0.13
  25. Hao Li · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.